Biomarkers and Precision Medicine: State of the Art
Biomarkers and Precision Medicine: State of the Art
复制标题
DOI：
10.1016/j.ccc.2019.08.012
复制
发表时间：
2020-01-01
影响因子：
4.3
通讯作者：
Ware, Lorraine B.
中科院分区：
文献类型：
--
作者：
Sarma, Aartik;Calfee, Carolyn S.;Ware, Lorraine B.
危重病综合征，包括败血症和急性呼吸窘迫综合征（ARDS），使用基于广泛的临床可用标准的共识定义进行识别，并包括具有异质性生物学的患者。这种异质性是开发和测试这些综合征的有效疗法的障碍。生物标志物鉴定ARDS和脓毒症的临床上不同的分子表型。这些分子表型与死亡率的差异相关，并在临床试验的回顾性分析中预测对几种治疗的反应。生物标志物可用于危重病临床试验的预后和预测富集，以将精准医学纳入重症监护。
Critical illness syndromes, including sepsis and the acute respiratory distress syndrome (ARDS), are identified using consensus definitions that are based on broad, clinically available criteria and include patients with heterogeneous biology. This heterogeneity is a barrier to developing and testing effective therapies for these syndromes. Biomarkers identify clinically distinct molecular phenotypes of ARDS and sepsis. These molecular phenotypes are associated with differences in mortality and predict response to several treatments in retrospective analyses of clinical trials. Biomarkers can be used for prognostic and predictive enrichment of clinical trials in critical illness to incorporate precision medicine in critical care.